Bone Metastasis Diagnostic Kit Detecting Osteocalcin and N-Cadherin
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for bone metastasis of cancer are ineffective in early detection, leading to late-stage diagnosis and poor treatment outcomes, as they only become apparent when bone tissue destruction has already progressed.
Innovation Solution
A diagnostic composition and kit that detect cells released into the blood expressing osteocalcin and N-cadherin using agents such as antibodies, aptamers, DNA, RNA, or proteins, allowing for early identification of bone metastasis before significant bone tissue destruction occurs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging tests (bone scanning) are used for diagnosis, then diagnosis is possible, but diagnosis occurs only at late stage when bone tissue destruction has already progressed
Solution Approach 1:
The patent detects osteocalcin and N-cadherin in blood samples during the microscopic bone metastasis stage, performing detection before bone tissue destruction occurs. This preliminary detection enables early intervention while the disease is still treatable, resolving the contradiction between achieving diagnosis and preserving treatment effectiveness.
2Reliability
If bone scanning is performed every 6 to 12 months for prevention, then early detection is attempted, but bone metastasis is still diagnosed late when bone destruction has progressed
Solution Approach 1:
The patent replaces conventional mechanical imaging tests (bone scanning) with a biochemical detection method measuring osteocalcin and N-cadherin in blood samples. This substitution enables detection at the microscopic metastasis stage before bone tissue changes occur, achieving both high reliability and early timing.
3Measurement precision
If diagnosis is made at clinical bone metastasis stage, then morphological changes in bone tissue are visible, but effective treatment becomes difficult due to progression
Solution Approach 1:
The patent performs detection of osteocalcin and N-cadherin in the microscopic bone metastasis stage, acting preliminarily before bone tissue destruction and clinical symptoms occur. This timing enables treatment intervention when the disease is still manageable, resolving the contradiction between diagnosis precision and treatment effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables earlier diagnosis of bone metastasis, significantly advancing the timing of detection and potentially increasing patient survival rates by identifying microscopic bone metastasis stages before tissue destruction.
Implementation Method 1
The agent for detecting cells released into blood expressing osteocalcin is at least one selected from the group consisting of antibodies, aptamers, DNA, RNA, proteins, and polypeptides
Data Source
Figure 1
Figure 2
Figure 3(a)~3(b)
AI summary
A composition and a kit of the present invention are capable of detecting osteocalcin and N-cadherin, which are biomarkers of circulating osteocalcin-positive cells that are released in the microscopic bone metastasis stage of cancer. Thus, the composition and the kit may diagnose metastatic bone cancer early. In addition, a method of providing information for early diagnosis of bone metastasis of cancer according to the present invention may increase the survival rate of metastatic bone cancer patients.